Radiation protection considerations for patients receiving I-131 therapy for carcinoma of the thyroid

09 Nov 2018
17:35 - 17:55

Radiation protection considerations for patients receiving I-131 therapy for carcinoma of the thyroid

At the Bank of Cyprus Oncology Centre (BOCOC) patients, who have received therapeutic activities of I-131 (more than 100mCi or 3700MBq) for the treatment of thyroid cancer, following the removal of the thyroid gland, are hospitalised for at least 2 days until radiation exposure rates drop to acceptable levels as suggested by European Commission’s guidance RP-97.  A number of practical issues need to be considered  and preventative measures need to be taken to reduce exposure to personnel, members of the public and patient’s family members  according to the ALARA principle (As Low As Reasonably Achievable)  as required by the ICRP (International Commission on Radiological Protection) and National Legislation. We present the measures taken at the BOCOC to minimise exposure and prevent contamination in the hospital but also the radiation safety precautions taken to minimise radiation exposure to family members and comforters and carers following the release of the patient from the hospital.